MannKind Corporation (MNKD)
$3.29-3.80%Close
SELLCRISIS · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV40.0%–380.7%
- Market cap
- $1.0B
- Beta
- 1.10
- P/E (TTM)
- -26.59
- IV-%ile
- 81
- IV ATM
- 128.2%
- Short % float
- 8.63%
- Days to cover
- 4.4
- SI change
- -11.0%
- 1W
- -13.42%
- 1M
- -13.19%
- vs SPY 1W
- -14.58%
- vs SPY 1M
- -16.18%
Industry peers
FMP comparable companies · ranked by market cap
- ABCLBUYAbCellera Biologics Inc.$4.2BCRISISQ -6$13.74+4.41%
- HRMYSELLHarmony Biosciences Holdings, Inc.$2.3BBEARQ 1$39.64+1.72%
- VERASELLVera Therapeutics, Inc.$2.2BCRISISQ 21$30.42+0.50%
- CLDXSELLCelldex Therapeutics, Inc.$2.1BCRISISQ 5$31.65+2.01%
- AUPHSELLAurinia Pharmaceuticals Inc.$2.0BBEARQ 22$15.83+2.65%
- BHVNSELLBiohaven Ltd.$1.9BCRISISQ 17$12.87+1.26%
- NUVBSELLNuvation Bio Inc.$1.8BCRISISQ 4$5.14+1.01%
- IMCRSELLImmunocore Holdings plc$1.5BBEARQ 2$29.71+1.03%
- JANXBUYJanux Therapeutics, Inc.$1.0BRECOVERYQ 12$16.93-0.59%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on MNKD?
- LOPJLB’s latest quantitative signal on MannKind Corporation (MNKD) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MNKD in?
- MannKind Corporation (MNKD) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MannKind Corporation (MNKD) do?
- MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKin…